Top Story

Novel olaparib combination shows activity in ovarian, breast cancers

May 1, 2015

PHILADELPHIA — A combination treatment composed of the PARP inhibitor olaparib and the investigational PI3K inhibitor BKM120 demonstrated activity and safety for women with triple-negative breast cancer or high-grade serous ovarian cancer, according to study findings presented at the American Association for Cancer Research Annual Meeting.

High-grade serous ovarian cancer and triple-negative breast cancer are similar in that they often have germline BRCA mutations, have a sensitivity to platinum agents and have high copy number alterations based on The Cancer Genome Atlas, according to study background. Further, preclinical data have suggested olaparib (Lynparza, AstraZeneca) is synergistic with BKM120 (Novartis) and BYL719 (Novartis) in both cancers.

In the Journals

Quadrivalent HPV vaccine provides early benefit in adolescent girls

May 1, 2015
Girls aged between 14 and 17 years experienced early beneficial effects with the quadrivalent HPV vaccine; therefore, offering additional justification for not delaying…
VIDEO: HPV vaccination trial provides 'reassuring' data on multisite protection Meeting News CoverageVideo

VIDEO: HPV vaccination trial provides 'reassuring' data on multisite protection

April 28, 2015
Barbara Burtness, MD, professor of medical oncology at Yale Cancer Center and a HemOnc Today Editorial Board member, comments on results of the Costa Rica Vaccine Trial…
Meeting News Coverage

Top 5 lessons learned at SGO's Women's Cancer Annual Meeting

April 27, 2015
Surgical and medical approaches to ovarian cancer, sentinel node mapping for endometrial cancer, the use of tissue morcellation for uterine tissue extraction, and the…
CME
Hematology Oncology Case Consults

Diagnosis and Management of Hemophilia

No commercial support for this activity.

This CME activity will focus on the diagnosis and management of the patient with hemophilia supplemented with a case…
More »
Meeting News Coverage Video
4131332248001 th

Antibody-drug conjugate shows promise for NSCLC, ovarian cancer

June 12, 2014
CHICAGO — Howard A. Burris, MD, chief medical officer at the Sarah Cannon Research Institute, offers his…
More »
CME
Activity cover

Targeted Therapy and Immunotherapy in the Management of Metastatic Melanoma: 2014 Updates

This activity is supported by an educational grant from Merck & Co., Inc.

Melanoma remains a challenging condition for clinicians. An array of targeted therapies and immunotherapy are in…
More »
Meeting News Coverage

Novel olaparib combination shows activity in ovarian, breast cancers

May 1, 2015
PHILADELPHIA — A combination treatment composed of the PARP inhibitor olaparib and the investigational PI3K inhibitor BKM120 demonstrated…
In the Journals

Quadrivalent HPV vaccine provides early benefit in adolescent girls

May 1, 2015
Girls aged between 14 and 17 years experienced early beneficial effects with the quadrivalent HPV vaccine; therefore, offering additional…
VIDEO: HPV vaccination trial provides 'reassuring' data on multisite protection Meeting News CoverageVideo

VIDEO: HPV vaccination trial provides 'reassuring' data on multisite protection

April 28, 2015
Barbara Burtness, MD, professor of medical oncology at Yale Cancer Center and a HemOnc Today Editorial Board member, comments on results of the…
Meeting News Coverage

Top 5 lessons learned at SGO's Women's Cancer Annual Meeting

April 27, 2015
Surgical and medical approaches to ovarian cancer, sentinel node mapping for endometrial cancer, the use of tissue morcellation for uterine tissue…
FDA News

FDA grants orphan drug designation to Cantrixil for ovarian cancer

April 22, 2015
The FDA granted orphan drug designation to TRXE-002 for the treatment of patients with ovarian cancer, according to a press release from…
Daniel C. Beachler, PhD Meeting News CoveragePerspective

HPV vaccine offers multisite protection, even among previously exposed women

April 21, 2015
PHILADELPHIA — HPV vaccination of women aged 18 to 25 years provides strong combined protection against HPV 16/18 infection at three anatomical…
In the Journals

Breast, ovarian cancer risks vary by BRCA mutation location, type

April 10, 2015
The risks for breast and ovarian cancers varied based on the type and location of BRCA1 and BRCA2 mutations, according to the results of an…
In the Journals

Intraperitoneal chemotherapy prolongs OS in advanced ovarian cancer

April 7, 2015
Intraperitoneal chemotherapy was associated with long-term survival benefits compared with IV chemotherapy in patients with advanced ovarian cancer…
Robert L. Coleman, MD FDA News

FDA grants breakthrough therapy designation to rucaparib for advanced ovarian cancer

April 7, 2015
The FDA today granted breakthrough therapy designation to rucaparib as monotherapy for patients with advanced ovarian cancer, according to a press…
In the Journals

Early alopecia linked to favorable outcomes in epithelial ovarian cancer

April 2, 2015
Patients with primary epithelial ovarian cancer who experienced early-onset grade 2 alopecia with chemotherapy demonstrated significantly improved…
More Headlines »
morganatic-roan